120 related articles for article (PubMed ID: 38071595)
1. Multiple myeloma, haematologic malignancy and immunosuppressant and immunomodulatory medications are associated with sebaceous carcinoma, a pharmacovigilance study of the FDA adverse event reporting system.
Jedlowski PM; DuPont JP
J Eur Acad Dermatol Venereol; 2024 May; 38(5):937-944. PubMed ID: 38071595
[TBL] [Abstract][Full Text] [Related]
2. A retrospective analysis of drugs associated with the development of cutaneous squamous cell carcinoma reported by patients on the FDA's adverse events reporting system.
Jean-Pierre P; Nouri K
Arch Dermatol Res; 2024 May; 316(6):250. PubMed ID: 38795220
[TBL] [Abstract][Full Text] [Related]
3. DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020.
Jedlowski PM; Jedlowski MF; Fazel MT
Am J Clin Dermatol; 2021 Nov; 22(6):891-900. PubMed ID: 34287770
[TBL] [Abstract][Full Text] [Related]
4. Association of Nonmelanoma Skin Cancers, Melanoma, and Merkel Cell Carcinoma with Dermatologic Medications: A Case-Control Pharmacovigilance Study of the FDA Adverse Events Reporting System.
Jedlowski PM
Dermatology; 2023; 239(5):694-699. PubMed ID: 37054693
[TBL] [Abstract][Full Text] [Related]
5. Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system.
Jiang T; Su H; Li Y; Wu Y; Ming Y; Li C; Fu R; Feng L; Li Z; Li L; Ni R; Liu Y
Front Pharmacol; 2022; 13():989032. PubMed ID: 36532784
[No Abstract] [Full Text] [Related]
6. Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study.
Huang J; Cai J; Ye Q; Jiang Q; Lin H; Wu L
BMJ Open; 2023 Aug; 13(8):e071456. PubMed ID: 37536976
[TBL] [Abstract][Full Text] [Related]
7. Sebaceous Carcinoma Incidence and Survival Among Solid Organ Transplant Recipients in the United States, 1987-2017.
Sargen MR; Cahoon EK; Lynch CF; Tucker MA; Goldstein AM; Engels EA
JAMA Dermatol; 2020 Dec; 156(12):1307-1314. PubMed ID: 33146669
[TBL] [Abstract][Full Text] [Related]
8. Ingenol Mebutate Is Associated With Increased Reporting Odds for Squamous Cell Carcinoma in Actinic Keratosis Patients, a Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).
Jedlowski PM
J Cutan Med Surg; 2023; 27(1):39-43. PubMed ID: 36495205
[TBL] [Abstract][Full Text] [Related]
9. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
10. Anaplastic lymphoma kinase tyrosine kinase inhibitors associated gastrointestinal obstruction, perforation, and ulceration: an analysis of the FDA adverse event reporting system database (FAERS).
Huang J; Zhao Y; Cao Y; Zhang Q; Ran D; Li J; Luo L; Qiu F; Meng L
Int J Clin Pharm; 2022 Aug; 44(4):993-1003. PubMed ID: 35776375
[TBL] [Abstract][Full Text] [Related]
11. Topical ophthalmic beta-blockers are associated with ocular pseudopemphigoid: A pharmacovigilance study of antiglaucoma medications utilising the FDA adverse event reporting system.
Jedlowski PM; Jedlowski MF
Australas J Dermatol; 2022 May; 63(2):222-227. PubMed ID: 35316535
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular complications of modern multiple myeloma therapy: A pharmacovigilance study.
Al-Yafeai Z; Ghoweba M; Ananthaneni A; Abduljabar H; Aziz D
Br J Clin Pharmacol; 2023 Feb; 89(2):641-648. PubMed ID: 35996166
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
Verden A; Dimbil M; Kyle R; Overstreet B; Hoffman KB
Drug Saf; 2018 Apr; 41(4):357-361. PubMed ID: 29196988
[TBL] [Abstract][Full Text] [Related]
14. A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab.
Chen Z; Li M; Li S; Li Y; Wu J; Qiu K; Yu X; Huang L; Chen G
Expert Opin Drug Saf; 2023 Apr; 22(4):339-342. PubMed ID: 36178002
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Prednisone Avoidance in Patients With Liver Transplant Using the U.S. Food and Drug Administration Adverse Event Reporting System.
Ogura T; Shiraishi C
Cureus; 2024 May; 16(5):e60193. PubMed ID: 38868240
[TBL] [Abstract][Full Text] [Related]
16. Acute renal failure and cardiac arrhythmias associated with remdesivir use in patients with COVID-19 infections: Analysis using the US FDA adverse event reporting system.
Orogun L; Chyou TY; Nishtala PS
Int J Risk Saf Med; 2023; 34(2):87-99. PubMed ID: 37154187
[TBL] [Abstract][Full Text] [Related]
17. Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS).
Omar NE; Fahmy Soliman AI; Eshra M; Saeed T; Hamad A; Abou-Ali A
ESMO Open; 2021 Dec; 6(6):100315. PubMed ID: 34864500
[TBL] [Abstract][Full Text] [Related]
18. Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database.
Liu W; Du Q; Guo Z; Ye X; Liu J
Front Pharmacol; 2023; 14():1283247. PubMed ID: 38027003
[No Abstract] [Full Text] [Related]
19. An exploratory study evaluating the 30 medications most commonly associated with headaches in the FDA Adverse Event Reporting System.
Musialowicz B; Kamitaki B; Zhang P
Headache; 2023 Feb; 63(2):299-304. PubMed ID: 36651638
[TBL] [Abstract][Full Text] [Related]
20. Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS).
Kong W; Mao W; Zhang L; Wu Y
Front Pediatr; 2022; 10():1069504. PubMed ID: 36714649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
